MAPT and Alzheimer disease: These data reinforce the idea that A2AR dysfunction plays a role in AD pathogenesis, involving both amyloid and tau-related synaptic and memory deficits by two independent mechanisms, and, hence, may constitute a relevant therapeutic target against AD-related early synaptic loss.